Inhibitors | CYP2C8 | CYP3A4 | ||||||
---|---|---|---|---|---|---|---|---|
Max (nm) | Trough (nm) | Binding Type | Ks(μM) | Max (nm) | Trough (nM) | Binding Type | Ks (μM) | |
Ketoconazle | 431 | 389 | II | NA | 429 | 390 | II | NA |
Afatinib | 419 | 404 | II | NA | —a | NA | ||
Axitinib | 421 | 400 | II | 2.2 | 428 | 410 | II | 4.5 |
Bosutinib | —a | NA | 429 | 413 | II? | NA | ||
Dasatinib | —a | NA | 428 | 419 | II? | NA | ||
Erlotinib | 417 | 399 | II | 12.6 | —a | NA | ||
Gefitinib | 410 | 399 | II? | NA | 424 | 412 | II? | NA |
Imatinib | 429 | 410 | II | 23.5 | 424 | 410 | II | 18.1 |
Lapatinib | 429 | 417 | II? | NA | —a | NA | ||
Nilotinib | 429 | 401 | II | 0.5 | 427 | 404 | II | 2.2 |
Pazopanib | 411 | 401 | II? | NA | 429 | 409 | II | 0.8 |
Sorafenib | 411 | 389 | II | 1.7 | 390 | 420 | I | 3.0 |
Sunitinib | —a | NA | —a | NA |
NA, data not available (Ks values could not be accurately determined due to weak binding and less-defined spectra).
↵a A well defined spectrum could not be obtained due to weak binding.